United States HR 5086: Safe Disposal of Opioids Act of 2021

Status: Referred to the Subcommittee on Health. (as of 2021-08-25)

State: United States · Session: 117 · Bill: HR 5086

Sponsors: Suzanne Bonamici, Alexander X. Mooney, Ann M. Kuster, Brian K. Fitzpatrick, Mike Kelly, Susan Wild

Bill Text

I 
117THCONGRESS 
1
STSESSION 
H. R. 5086 
To  amend  the  Comprehensive  Addiction  and  Recovery  Act  of  2016  to  author-
ize   the   Attorney   General,   in   coordination   with   the   Administrator   of   
the   Drug   Enforcement   Administration,   the   Secretary   of   Health   and   
Human  Services,  and  the  Director  of  the  Office  of  National  Drug  Control  
Policy,  to  award  grants  to  covered  entities  to  establish  or  maintain  
disposal  sites  for  unwanted  prescription  medications,  and  for  other  pur-
poses. 
IN  THE  HOUSE  OF  REPRESENTATIVES  
AUGUST24, 2021 
Ms.  B
ONAMICI(for  herself,  Mr.  MOONEY,  Ms.  KUSTER,  Mr.  FITZPATRICK, 
and  Ms.  W
ILD)  introduced  the  following  bill;  which  was  referred  to  the  
Committee on Energy and Commerce 
A  BILL  
To  amend  the  Comprehensive  Addiction  and  Recovery  Act  
of  2016  to  authorize  the  Attorney  General,  in  coordina-
tion  with  the  Administrator  of  the  Drug  Enforcement  
Administration,   the   Secretary   of   Health   and   Human   
Services,  and  the  Director  of  the  Office  of  National  Drug  
Control  Policy,  to  award  grants  to  covered  entities  to  
establish  or  maintain  disposal  sites  for  unwanted  pre-
scription medications, and for other purposes. 
Be  it  enacted  by  the  Senate  and  House  of  Representa-1
tives of the United States of America in Congress assembled, 2
VerDate Sep 11 2014     02:07 Aug 25, 2021    Jkt 019200    PO 00000    Frm 00001    Fmt 6652    Sfmt 6201    E:\BILLS\H5086.IH    H5086
kjohnson on DSK79L0C42PROD with BILLS

2 
•HR  5086  IH
SECTION 1. SHORT TITLE. 1
This  Act  may  be  cited  as  the  ‘‘Safe  Disposal  of  2
Opioids Act of 2021’’. 3
SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRE-4
SCRIPTION MEDICATIONS. 5
Section  203  of  the  Comprehensive  Addiction  and  Re-6
covery  Act  of  2016  (21  U.S.C.  822a)  is  amended  by  add-7
ing at the end the following: 8
‘‘(c)  G
RANTS  FORDISPOSALSITES  FORUNWANTED 9
P
RESCRIPTIONMEDICATIONS.— 10
‘‘(1) G
RANTS.— 11
‘‘(A)  A
WARDS.—In  carrying  out  subsection  12
(b),  the  Attorney  General  shall  award  grants  to  13
covered  entities  to  establish  or  maintain  dis-14
posal  sites  for  unwanted  prescription  medica-15
tions. 16
‘‘(B)  L
IMITATION.—Of  the  total  amount  of  17
awards   under   subparagraph   (A)   for   a   fiscal   18
year,   the   Attorney   General   shall   not   award   19
more  than  10  percent  to  covered  entities  that  20
are— 21
‘‘(i)  State,  local,  or  tribal  law  enforce-22
ment agencies; or 23
‘‘(ii)   manufacturers,   distributors,   or   24
reverse  distributors  of  prescription  medica-25
tions. 26
VerDate Sep 11 2014     02:07 Aug 25, 2021    Jkt 019200    PO 00000    Frm 00002    Fmt 6652    Sfmt 6201    E:\BILLS\H5086.IH    H5086
kjohnson on DSK79L0C42PROD with BILLS

3 
•HR  5086  IH
‘‘(2) DISCOUNTS  FOR  ELIGIBLE  PATIENTS.— 1
‘‘(A)    I
NGENERAL.—The    Secretary    of    2
Health  and  Human  Services  shall  establish  a  3
mechanism  by  which  amounts  paid  by  an  eligi-4
ble  patient  for  an  active  opioid  are  discounted  5
at  time  of  payment  or  purchase  to  ensure  that  6
such  patient  does  not  pay  any  amount  attrib-7
utable  to  a  fee  under  paragraph  (3),  with  as  lit-8
tle burden on the patient as possible. 9
‘‘(B)  D
EFINITION.—For  purposes  of  sub-10
paragraph    (A),    the    term    ‘eligible    patient’    11
means— 12
‘‘(i)  a  patient  for  whom  any  active  13
opioid  (as  so  defined)  is  prescribed  to  treat  14
pain  relating  to  cancer  or  cancer  treat-15
ment; 16
‘‘(ii)  a  patient  participating  in  hospice  17
care; and 18
‘‘(iii)  in  the  case  of  the  death  or  inca-19
pacity  of  a  patient  described  in  subpara-20
graph  (A)  or  (B)  or  any  similar  situation  21
as  determined  by  the  Secretary  of  Health  22
and  Human  Services,  the  appropriate  fam-23
ily  member,  medical  proxy,  or  similar  rep-24
resentative or the estate of such patient. 25
VerDate Sep 11 2014     02:07 Aug 25, 2021    Jkt 019200    PO 00000    Frm 00003    Fmt 6652    Sfmt 6201    E:\BILLS\H5086.IH    H5086
kjohnson on DSK79L0C42PROD with BILLS

4 
•HR  5086  IH
‘‘(3) FEES.— 1
‘‘(A)  I
N   GENERAL.—There  is  hereby  im-2
posed  on  the  sale  of  any  active  opioid  by  the  3
manufacturer,  producer,  or  importer  a  fee  equal  4
to 1 cent per 100 milligrams so sold. 5
‘‘(B) S
PECIAL  RULES.— 6
‘‘(i)  D
EFINITION.—In  this  paragraph,  7
the term ‘active opioid’— 8
‘‘(I)   means   any   controlled   sub-9
stance  (as  defined  in  section  102  of  10
the  Controlled  Substances  Act,  as  in  11
effect  on  the  date  of  the  Safe  Disposal  12
of   Opioids   Act   of   2021)   which   is   13
opium,  an  opiate,  or  any  derivative  14
thereof; and 15
‘‘(II)    excludes    any    prescribed    16
drug  which  is  used  exclusively  for  the  17
treatment  of  opioid  

View United States HR 5086 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.